Prostacyclin (PGI2) is a metabolite of arachidonic acid, generated by the arterial wallsl 2 and secreted into the circulation by the lungs. 3 In man, it blocks platelet aggregation, disperses circulating platelet aggregates, and causes vasodilatation. 4 It might well be that prostacyclin shields arteries against mural thrombosis and stops development of atherosclerosis. 5 The remarkable properties of prostacyclin have been found beneficial in treating advanced arteriosclerosis obliterans.6 They could also be useful in the management of atherosclerotic heart disease provided more was known about the haemodynamic effects of prostaglandin in man.
Patients and methods
The study included 10 men, aged 34 to 65 years, who underwent treatment with prostacyclin because of peripheral arterial disease. Arteriosclerosis obliterans was diagnosed in seven of them, and thrombangiitis in the remaining three. The diagnosis was based on typical history, clinical examination, and in each case it was confirmed by angiography. There was no evidence of either coronary heart disease or cardiac failure. group.bmj.com on July 8, 2017 -Published by http://heart.bmj.com/ Downloaded from cubital vein. The catheter was connected to a 756 pressure transducer and 863 amplifier of Mingograf 82 recorder (Elema-Siemens) from which measurements of right atrial, right ventricular, pulmonary artery, and pulmonary capillary wedge pressures were made. Cardiac output was measured using the thermodilution technique in triplicate, and the mean was calculated. Arterial blood pressure was determined continuously through a cannula inserted into the left brachial artery.
Cardiac output, stroke volume, and both left and right ventricular stroke work were expressed as indices by dividing by body surface. In calculating the left ventricular stroke work index pulmonary artery end-diastolic pressure was used instead of left ventricular end-diastolic pressure. Peripheral vascular resistance, total pulmonary resistance, and pulmonary wedge resistance were calculated by the standard formulae.
Simultaneously, external systolic time intervals were measured from the carotid artery and praecordial phonocardiogram and electrocardiogram.
The differences between time intervals after correction for standard heart rate were compared.7 Left ventricular dP/dtmax was calculated by the indirect method8 using the following formula for mean electromechanical Ap/At: BPd-PAEDP/PEP, where BPd is diastolic blood pressure in the brachial artery, PAEDP is pulmonary artery end-diastolic pressure, and PEP is pre-ejection period.
Additionally, in three of 10 patients both resting and hyperaemic calf muscle blood flows in the affected limbs were A similar dose-dependent fall in pulmonary vascular resistance after PGI 2 injection was reported recently in several experimental animal models. 10 11 Man, however, appears to be more sensitive to PGI2 than the animals studied. Infusion of five to 10 times lower concentrations of prostacyclin to man than to the animals10 12 13 resulted in a similar fall in pulmonary vascular resistance in both groups.
In comparison to prostaglandin E1 (PGE1) prostacyclin has a stronger vasodilatatory action in man. Doses of PGE,14 at least twice as high were necessary to reduce pulmonary vascular resistance to the range similar to that reported here. Prostacy-clin was also better tolerated than PGE1. We have not observed abdominal cramps or back pain, which were frequently recorded in subjects receiving PGE1, and which had necessitated interruption of the infusion. 15 Although PGI2 depressed significantly total pulmonary resistance, its effects on the pulmonary bed were less pronounced than those on peripheral vascular resistance. Thus, during the administration of PGI2 at a dose of 10 ng/kg per min pulmonary wedge resistance fell by were these differences of striking magnitude, they nevertheless might suggest that the two vascular beds vary in sensitivity to PGI2. This observation seems interesting, since the sensitivity to the vasodilatating action of prostaglandins varies between the different vascular regions, being highest in the skeletal muscle vasculature and lowest in the splanchnic vascular bed. Moreover, in the skeletal muscle vascular bed, the PGI2 synthetic pathway is quantitatively the most important."7
The falling vascular resistance caused a drop in arterial blood pressure, reaching the level of significance at a dose 10 ng/kg per min. The acceleration of heart rate, which followed, could be looked upon as an autoregulatory mechanism, triggered by a fall in blood pressure. This acceleration together with a slight fall in stroke volume index resulted in the small increase in cardiac index, which did not reach the level of statistical significance. Left ventricular stroke work index decreased significantly during infusion of 10 We thank The Upjohn Company for a grant for equipment.
